Valeant launches hostile $53B bid for Allergan

June 18, 2014

Valeant Pharmaceuticals said Wednesday it has launched a tender offer for Allergan, the maker of Botox, taking its hostile bid directly to shareholders.

The cash and stock offer values Allergan Inc. at around $53 billion, and it expires Aug. 15.

Allergan said it will review the offer and said shareholders shouldn't take action on the right now.

Valeant, which is based in Canada, has teamed up with Bill Ackman's Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their original bid of about $45.6 billion several times.

Allergan, of Irvine, California, has said the latest offer is still too low.

Ackman—whose Pershing Square is Allergan's biggest —is also moving to replace most of Allergan's board.

On Tuesday Valeant Pharmaceuticals International Inc. said it planned to take a buyout offer directly to Allergan shareholders this week.

Allergan shares rose $1.74 to $162.27 in morning trading. Valeant stock added 13 cents to $119.

Explore further: Allergan board turns down Valeant takeover offer (Update)

Related Stories

Allergan board turns down Valeant takeover offer (Update)

May 12, 2014

Botox maker Allergan formally rejected on Monday a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited offer worth nearly $46 billion undervalues the company and poses a significant risk to its growth prospects.

Valeant raises cash-stock offer for Allergan (Update)

May 28, 2014

Valeant Pharmaceuticals has pumped more cash into its bid for Botox maker Allergan, and it also defended its business model on Wednesday, a day after its reluctant acquisition target aired more concerns about a deal.

Valeant planning hostile bid for Allergan

June 17, 2014

Valeant plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals that have risen as high as $53 billion.

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.